Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 years old, and the AMD therapeutics market is driven by the increasing prevalence of the disease. The market is also influenced by the growing demand for effective treatments that can slow or halt the progression of the disease, as well as the high unmet need for therapies that can restore lost vision. Key players in the Age-related Macular Degeneration market include pharmaceutical companies such as Novartis AG, Roche AG, and Regeneron Pharmaceuticals, Inc., which are developing novel therapies based on gene therapy and monoclonal antibodies. The market is also characterized by strong research and development activities, with ongoing clinical trials aimed at testing the safety and efficacy of new therapeutics for AMD.
Leading Companies in the Age-related Macular Degeneration Industry:
Novartis International AG
Novartis International AG is a Swiss multinational pharmaceutical company that was founded in 1996. Its headquarters are located in Basel, Switzerland, and it operates in over 140 countries worldwide. In October 2022, Novartis announced the initiation of a Phase III clinical trial of its investigational gene therapy, which aims to halt the progression of age-related macular degeneration (AMD).
Bayer AG
Bayer AG is a German multinational pharmaceutical and life sciences company that was founded in 1863. Its headquarters are located in Leverkusen, Germany, and it operates in over 90 countries worldwide. In September 2022, the US FDA approved Bayer's drug, Eylea, for the treatment of neovascular age-related macular degeneration.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that was founded in 1988. Its headquarters are located in Tarrytown, New York, and it operates in over 30 countries worldwide. In October 2022, Regeneron announced positive Phase III clinical trial results for its investigational drug, RTH258, for the treatment of neovascular age-related macular degeneration.